drugset / Trial / NCT00004032

Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer

NCT00004032

Phase 1 Completed 12 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase I trial to study the effectiveness of a tumor cell vaccine and interferon gamma in patients with refractory epithelial ovarian cancer. Vaccines made from a person's cancer cells may make the body build an immune response to and kill their tumor cells. Combining vaccine therapy with interferon gamma may be a more effective treatment for epithelial ovarian cancer

Timeline

Start
1997-10
Primary completion
2004-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject ALVAC-hB7.1 Unknown Other
Subject interferon gamma Protein / enzyme biologic Other